Natus Announces Preliminary 2021 Fourth Quarter and Full Year Revenue
10 Gennaio 2022 - 10:01PM
Natus Medical Incorporated (NASDAQ:NTUS) (the
“Company” or “Natus”), a leading provider of medical device
solutions focused on the diagnosis and treatment of central nervous
and sensory system disorders for patients of all ages, today
announced preliminary 2021 fourth quarter and full year revenue.
The Company expects to report revenue of
approximately $127.5 to $128.5 million for the fourth quarter of
2021, and full year 2021 of $472.3 to $473.3 million.
“We are pleased with the high single digit
revenue growth delivered by our Natus Teammates in the fourth
quarter despite supply chain constraints impacting the cost of
logistics and components,” said Thomas J. Sullivan, President &
Chief Executive Officer. “While we were able to overcome these
challenges and respond to customer demand, the incremental supply
chain costs limited incremental profitability.”
Natus will release its full 2021 financial
results after the market closes on February 24, 2021.
Forward-Looking Statements
This press release contains forward-looking
statements, which are generally statements that are not historical
facts. Forward-looking statements can be identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans”, “will”, “outlook” and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. These statements relate to current estimates and assumptions
of our management as of the date of this press release and involve
known and unknown risks, uncertainties and other factors that may
cause actual results, levels of activity, performance, or
achievements to differ materially from those expressed or implied
by the forward-looking statements. Forward-looking statements are
only predictions and the actual events or results may differ
materially. Natus cannot provide any assurance that its future
results or the results implied by the forward-looking statements
will meet expectations. The Company's future results could differ
materially due to a number of factors, including supply chain
delays and constraints, the business, social and economic impact of
the COVID-19 pandemic on the Company's business and results of
operations, the ability of the Company to realize the anticipated
benefits from its new structure or from its consolidation strategy,
effects of competition, the Company's ability to successfully
integrate and achieve its profitability goals from recent
acquisitions, the demand for Natus products and services, the
impact of adverse global economic conditions and changing
governmental regulations, including foreign exchange rate changes,
on the Company's target markets, the Company's ability to expand
its sales in international markets, the Company's ability to
maintain current sales levels in a mature domestic market, the
Company's ability to control costs, risks associated with bringing
new products to market, and the Company's ability to fulfill
product orders on a timely basis, as well as those factors
identified under the heading Item 1A “Risk Factors” in the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2020. Natus disclaims any obligation to update
information contained in any forward looking statement, except as
required by law.
About Natus Medical
Incorporated
Natus is a leading provider of medical device
solutions focused on the diagnosis and treatment of central nervous
and sensory system disorders for patients of all ages.
Additional information about Natus Medical can
be found at www.natus.com.
Natus Medical IncorporatedB. Drew
DaviesExecutive Vice President and Chief Financial Officer(925)
223-6700InvestorRelations@Natus.com
Grafico Azioni Natus Medical (NASDAQ:NTUS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Natus Medical (NASDAQ:NTUS)
Storico
Da Set 2023 a Set 2024